Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Adenine phosphoribosyltransferase (APRT) is an enzyme that plays a crucial role in the purine salvage pathway, which recycles purines to maintain nucleotide pools and cellular energy balance. It catalyzes the conversion of adenine and 5-phosphoribosyl-1-pyrophosphate (PRPP) into adenosine monophosphate (AMP) and pyrophosphate. Deficiency in APRT activity causes adenine phosphoribosyltransferase deficiency, an autosomal recessive disorder characterized by recurrent kidney stones and risk for renal failure. APRT is a promising drug target for antiparasitic therapies since inhibition could selectively affect pathogen viability without harming host cells.
Inhibition of APRT activity, particularly in protozoan parasites
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Adenine phosphoribosyltransferase (None).